Available Trials
A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.
Bladder
-
IMMU-132 for Metastatic Urothelial Cancer
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
Breast
-
Post-Mastectomy/Lumpectomy Radiation after Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Gastrointestinal
-
Chemotherapy +/- Pembrolizumab in 1st Line Her2- Gastric or GEJ cancer
A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
-
Trastuzumab/Chemotherapy +/- Pembrolizumab in 1st Line Her2+ Gastric or GEJ Cancer
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
-
Nivolumab +/- Ipilimumab with Fluorouracil plus Cisplatin in Esophageal Squamous Cell
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
Head and Neck
-
Atezolizumab in Adjuvant Setting for Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (anti PD-L1 antibody) as Adjuvant Therapy after definitive local therapy in patients with high risk locally advanced Squamous Cell Carcinoma of the Head and Neck
Leukemia
-
Zanubrutinib vs. Ibrutinib for Relapsed/Refractory CLL/SLL
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
Azacitidine +/- Pevonedistat for High Risk MDS, CML, or Low-Blast AML
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Lung
-
Canakinumab for Adjuvant Non-Small Cell Lung Cancer
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer
Lymphoma
-
Zanubrutinib for Marginal Zone Lymphoma
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma (BGB-3111-214)
-
Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma
A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
-
Rituximab +/- Ibrutinib for Follicular Lymphoma
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
-
TGR-1202 in patients with DLBCL, FL, SLL, or MZL
A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Pancreatic
-
FOLFIRINOX +/- CPI-613 in Pancreatic Cancer
A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
-
Tumor Treating Fields with Gemzar/Nab-Paclitaxel for Pancreatic Cancer
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Prostate
-
Enzalutamide +/- Pembrolizumab in Prostate Cancer
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
Radiation Trial for Immediate Risk Prostate Cancer
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)
Solid Tumors
-
Cabozanitib +/- Atezolizumab in Solid Tumors
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
-
AVID100 in Patients with Advanced or Metastatic Solid Tumors
A phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100. an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin
-
INCMGA00012 in Solid Tumors
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors
-
Febrile Neutropenia Observational Trial
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
-
MGCD516 for Solid Tumor Malignancies
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies